BRKR
Bruker Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+44/100
Last price
60.50
▼ 3.36 (5.26%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
63.86
Day high
66.42
Day low
59.30
Volume
2.90M
Market cap
$9.22B
P/E (TTM)
—
52W range
32.37 – 66.98
Trailing performance
Returnvs SPY
1W
-6.22%
-8.2%
1M
+3.42%
+2.3%
3M
+5.75%
+1.2%
6M
+64.99%
+46.8%
YTD
+28.42%
+14.2%
1Y
+63.60%
+47.2%
3Y
-2.89%
-85.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BRKR open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+86.47K
Net buying
Buy transactions
14
101.94K shares
Sell transactions
7
15.47K shares
Net transactions
+21
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
41.09M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | MUNCH MARK ROBERT Officer |
CONVERSION | 2.00K | $44.38K | Direct |
| Sep 15, 26 | MUNCH MARK ROBERT Officer |
SELL | 2.00K | $105.74K | Direct |
| Aug 14, 26 | MUNCH MARK ROBERT Officer |
CONVERSION | 2.00K | $44.38K | Direct |
| Aug 14, 26 | BURES THOMAS Officer |
STOCK | 4.04K | $0 | Direct |
| Aug 14, 26 | LAUKIEN FRANK H Chief Executive Officer |
STOCK | 29.46K | $0 | Direct |
| Aug 14, 26 | MUNCH MARK ROBERT Officer |
STOCK | 14.44K | $0 | Direct |
| Aug 14, 26 | PRAUSE BURKHARD Officer |
STOCK | 3.30K | $0 | Direct |
| Aug 14, 26 | SREGA JUERGEN Officer |
STOCK | 16.90K | $0 | Direct |
| Aug 14, 26 | HERMAN GERALD N Chief Financial Officer |
STOCK | 15.79K | $0 | Direct |
| Aug 14, 26 | MUNCH MARK ROBERT Officer |
SELL | 2.00K | $115.20K | Direct |
| Jul 15, 26 | MUNCH MARK ROBERT Officer |
CONVERSION | 2.00K | $44.38K | Direct |
| Jul 15, 26 | MUNCH MARK ROBERT Officer |
SELL | 2.00K | $120.50K | Direct |
| Jun 15, 26 | MUNCH MARK ROBERT Officer |
CONVERSION | 2.00K | $44.38K | Direct |
| Jun 15, 26 | MUNCH MARK ROBERT Officer |
SELL | 2.00K | $109.52K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BUSSE FALKO |
Officer | 48.17K | Stock Award(Grant) |
HERMAN GERALD N |
Chief Financial Officer | 111.35K | Stock Award(Grant) |
LAUKIEN FRANK H |
Chief Executive Officer | 40.51M | Stock Award(Grant) |
LINTON WILLIAM A. |
Director | 63.24K | Stock Award(Grant) |
MUNCH MARK ROBERT |
Officer | 134.81K | Conversion of Exercise of derivative security |
ORNELL JOHN A |
Director | 39.73K | Stock Award(Grant) |
PACKER RICHARD A |
Director | 93.69K | Stock Award(Grant) |
REQUARDT HERMANN FRITZ |
Director | 30.96K | Stock Award(Grant) |
ROSENTHAL ROBERT JOHN |
Director | 38.78K | Stock Award(Grant) |
SREGA JUERGEN |
Officer | 174.63K | Stock Award(Grant) |
Fundamentals
Market cap$9.22B
Enterprise value$10.94B
Revenue (TTM)$3.50B
Gross profit$1.70B
EBITDA$541.10M
Net income$-106.90M
EPS (TTM)$-0.70
Free cash flow$179.94M
Total cash$184.90M
Total debt$1.86B
Book value / share$15.63
Shares outstanding152.36M
Float103.69M
Short % of float15.80%
Dividend yield0.33%
Beta (5Y)1.22
Valuation & profitability ratios
Trailing P/E—
Forward P/E25.29
PEG ratio1.52
Price / sales—
Price / book3.87
EV / revenue3.13
EV / EBITDA20.22
Gross margin48.48%
Operating margin9.88%
Profit margin-2.04%
Return on equity-3.00%
Return on assets3.14%
Debt / equity76.16
Current ratio1.85
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $3.44B | $3.37B | $2.96B | $2.53B | +2.1% |
| Operating revenue | $3.44B | $3.37B | $2.96B | $2.53B | +2.1% |
| Cost of revenue | $1.86B | $1.72B | $1.45B | $1.23B | +8.3% |
| Gross profit | $1.58B | $1.65B | $1.51B | $1.31B | -4.4% |
| Research & development | $395.20M | $376.50M | $294.80M | $235.90M | +5.0% |
| Selling, general & admin | $946.50M | $893.80M | $729.40M | $607.40M | +5.9% |
| Total operating expense | $1.34B | $1.27B | $1.02B | $843.30M | +5.6% |
| Operating income | $236.00M | $379.20M | $489.10M | $462.40M | -37.8% |
| Net interest income | -$46.70M | -$38.60M | -$5.20M | -$12.00M | -21.0% |
| Pre-tax income | $22.00M | $206.90M | $544.20M | $413.90M | -89.4% |
| Tax provision | $29.30M | $91.40M | $117.70M | $116.40M | -67.9% |
| Net income | -$8.60M | $113.10M | $427.20M | $296.60M | -107.6% |
| Net income to common | -$22.50M | $113.10M | $427.20M | $296.60M | -119.9% |
| Basic EPS | -0.15 | 0.76 | 2.92 | 2.00 | -119.7% |
| Diluted EPS | -0.15 | 0.76 | 2.90 | 1.99 | -119.7% |
| EBIT | $82.30M | $254.80M | $560.60M | $430.00M | -67.7% |
| EBITDA | $302.60M | $438.60M | $675.50M | $518.70M | -31.0% |
| Basic shares | 151.80M | 149.00M | 146.40M | 148.60M | +1.9% |
| Diluted shares | 151.80M | 149.50M | 147.20M | 149.40M | +1.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $298.80M | $183.40M | $488.30M | $645.50M | +62.9% |
| Cash & short-term investments | $298.80M | $183.40M | $488.30M | $645.50M | +62.9% |
| Accounts receivable | $544.90M | $565.50M | $492.00M | $472.70M | -3.6% |
| Inventory | $1.09B | $1.07B | $968.30M | $800.10M | +2.5% |
| Total current assets | $2.21B | $2.05B | $2.16B | $2.11B | +7.8% |
| Property, plant & equipment | $910.60M | $814.80M | $691.40M | $538.20M | +11.8% |
| Goodwill & intangibles | $2.45B | $2.42B | $913.10M | $728.50M | +1.1% |
| Total assets | $6.24B | $5.81B | $4.25B | $3.61B | +7.5% |
| Total current liabilities | $1.28B | $1.28B | $1.20B | $914.30M | -0.2% |
| Current debt | $16.60M | $32.50M | $121.20M | $18.70M | -48.9% |
| Long-term debt | $1.85B | $2.06B | $1.16B | $1.20B | -10.2% |
| Total debt | $2.04B | $2.25B | $1.38B | $1.27B | -9.0% |
| Total liabilities | $3.73B | $3.99B | $2.84B | $2.48B | -6.5% |
| Retained earnings | $2.36B | $2.41B | $2.32B | $1.93B | -1.9% |
| Working capital | $933.30M | $771.90M | $962.10M | $1.20B | +20.9% |
| Net tangible assets | $9.20M | -$638.60M | $464.10M | $385.30M | +101.4% |
| Shares issued | 152.14M | 182.46M | 175.94M | 175.39M | -16.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$8.30M | $113.80M | $428.50M | $298.50M | -107.3% |
| Depreciation & amortisation | $220.30M | $183.80M | $114.90M | $88.70M | +19.9% |
| Stock-based compensation | $20.20M | $25.30M | $30.90M | $27.70M | -20.2% |
| Change in working capital | -$144.80M | -$118.80M | -$87.80M | -$144.10M | -21.9% |
| Operating cash flow | $134.10M | $251.30M | $350.10M | $274.40M | -46.6% |
| Capital expenditure | -$120.20M | -$115.30M | -$106.90M | -$129.20M | -4.2% |
| Investing cash flow | -$196.50M | -$1.76B | -$326.00M | -$251.60M | +88.8% |
| Share buybacks | -$10.00M | $0 | -$152.30M | -$263.10M | — |
| Dividends paid | -$32.90M | -$30.20M | -$29.40M | -$29.80M | -8.9% |
| Financing cash flow | $135.10M | $1.23B | -$193.40M | -$415.30M | -89.0% |
| Free cash flow | $13.90M | $136.00M | $243.20M | $145.20M | -89.8% |
| End cash position | $303.10M | $186.70M | $491.60M | $648.70M | +62.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $838.50M | $823.40M | $977.20M | $860.50M | $797.40M | +1.8% |
| Operating revenue | $838.50M | $823.40M | $977.20M | $860.50M | $797.40M | +1.8% |
| Cost of revenue | $422.50M | $443.60M | $528.00M | $481.10M | $439.50M | -4.8% |
| Gross profit | $416.00M | $379.80M | $449.20M | $379.40M | $357.90M | +9.5% |
| Research & development | $94.30M | $101.30M | $99.60M | $98.30M | $100.20M | -6.9% |
| Selling, general & admin | $238.90M | $242.10M | $247.20M | $242.50M | $231.40M | -1.3% |
| Total operating expense | $333.20M | $343.40M | $337.40M | $344.40M | $331.60M | -3.0% |
| Operating income | $82.80M | $36.40M | $111.80M | $35.00M | $26.30M | +127.5% |
| Net interest income | -$2.50M | -$4.30M | -$12.30M | -$12.50M | -$12.80M | +41.9% |
| Pre-tax income | -$40.70M | $21.90M | $68.20M | -$71.80M | $500.00K | -285.8% |
| Tax provision | $14.20M | $2.50M | $37.80M | -$14.10M | -$3.10M | +468.0% |
| Net income | -$52.00M | $14.40M | $26.00M | -$59.60M | $7.60M | -461.1% |
| Net income to common | -$62.90M | $3.50M | $14.90M | -$62.40M | $7.60M | -1,897.1% |
| Basic EPS | -0.41 | 0.02 | 0.10 | -0.41 | 0.05 | -2,150.0% |
| Diluted EPS | -0.41 | 0.02 | 0.10 | -0.41 | 0.05 | -2,150.0% |
| EBIT | -$22.90M | $34.10M | $79.40M | -$51.50M | $16.20M | -167.2% |
| EBITDA | $35.10M | $92.40M | $137.50M | $4.20M | $72.30M | -62.0% |
| Basic shares | 152.30M | 152.20M | 152.00M | 151.80M | 151.60M | +0.1% |
| Diluted shares | 152.30M | 152.70M | 152.50M | 151.80M | 151.70M | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $184.90M | $133.40M | $298.80M | $293.10M | $92.00M | +38.6% |
| Cash & short-term investments | $222.50M | $133.40M | $298.80M | $293.10M | $92.00M | +66.8% |
| Accounts receivable | $545.90M | $542.70M | $544.90M | $550.90M | $522.60M | +0.6% |
| Inventory | $1.12B | $1.12B | $1.09B | $1.20B | $1.22B | -0.1% |
| Total current assets | $2.23B | $2.10B | $2.21B | $2.35B | $2.16B | +5.8% |
| Property, plant & equipment | $714.10M | $719.60M | $910.60M | $746.70M | $758.50M | -0.8% |
| Goodwill & intangibles | $2.30B | $2.48B | $2.45B | $2.47B | $2.62B | -7.2% |
| Total assets | $6.05B | $6.13B | $6.24B | $6.43B | $6.34B | -1.3% |
| Total current liabilities | $1.20B | $1.36B | $1.28B | $1.27B | $1.35B | -11.1% |
| Current debt | $10.10M | $8.40M | $16.60M | $24.30M | $55.70M | +20.2% |
| Long-term debt | $1.81B | $1.66B | $1.85B | $1.98B | $2.38B | +9.1% |
| Total debt | $1.82B | $1.67B | $2.04B | $2.01B | $2.44B | +9.2% |
| Total liabilities | $3.62B | $3.63B | $3.73B | $3.94B | $4.47B | -0.3% |
| Retained earnings | $2.29B | $2.36B | $2.36B | $2.35B | $2.42B | -3.0% |
| Shareholder equity | $2.38B | $2.45B | $2.46B | $2.43B | $1.80B | -2.8% |
| Working capital | $1.02B | $748.50M | $933.30M | $1.08B | $815.30M | +36.3% |
| Net tangible assets | $83.80M | -$26.20M | $9.20M | -$36.90M | -$814.80M | +419.8% |
| Shares issued | 152.35M | 152.22M | 152.14M | 182.92M | 182.70M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$50.90M | $15.70M | $29.20M | -$58.50M | $4.20M | — | -424.2% |
| Depreciation & amortisation | $58.00M | $58.30M | $58.10M | $55.70M | $56.10M | — | -0.5% |
| Change in working capital | -$196.90M | -$24.20M | $124.20M | -$118.00M | -$160.30M | — | -713.6% |
| Operating cash flow | -$77.40M | $71.20M | $229.80M | -$33.20M | -$127.50M | — | -208.7% |
| Capital expenditure | -$28.80M | -$24.20M | -$52.00M | -$20.90M | -$21.30M | — | -19.0% |
| Investing cash flow | -$25.30M | -$39.70M | -$55.50M | -$23.80M | -$91.10M | — | +36.3% |
| Share buybacks | — | $0 | $0 | $0 | $0 | -$10.00M | — |
| Dividends paid | -$18.50M | -$18.60M | -$17.60M | $0 | -$7.60M | — | +0.5% |
| Financing cash flow | $149.20M | -$204.90M | -$167.60M | $258.40M | $95.50M | — | +172.8% |
| Free cash flow | -$106.20M | $47.00M | $177.80M | -$54.10M | -$148.80M | — | -326.0% |
| End cash position | $189.10M | $137.60M | $303.10M | $297.30M | $96.20M | — | +37.4% |
Options analytics
Put / call volume
0.67
Call-heavy session
Put / call open interest
0.53
Positioning, not flow
Max pain
62.50
+3.3% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
97
Contracts, this expiry
Put volume
65
Contracts, this expiry
Heaviest call OI
67.50
238 contracts
Heaviest put OI
52.50
205 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.38 | 0.49 | +27.5% |
| Mar 2026 | 0.23 | 0.31 | +34.8% |
| Dec 2025 | 0.65 | 0.59 | -9.8% |
| Sep 2025 | 0.32 | 0.45 | +38.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.42 | 12 | $865.29M | +0.6% |
| Next quarter | 0.90 | 12 | $1.03B | +5.2% |
| Current year | 2.12 | 13 | $3.56B | +3.5% |
| Next year | 2.39 | 13 | $3.70B | +4.2% |
Analyst targets & ownership
Mean target$63.25
High target$80.00
Low target$50.00
Implied upside4.55%
Analyst count12
ConsensusBUY
Strong buy / Buy2 / 5
Hold5
Sell / Strong sell1 / 0
Held by insiders26.97%
Held by institutions95.37%
Institutions holding555
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
62.99
-3.96% from price
SMA 20
60.38
+0.19% from price
SMA 50
58.97
+2.59% from price
SMA 100
57.47
+5.27% from price
SMA 200
49.47
+22.29% from price
EMA 12
62.15
-2.66% from price
EMA 26
60.80
-0.49% from price
EMA 50
59.32
+1.99% from price
RSI (14)
49.5
Neutral
MACD (12,26,9)
1.36
Hist -0.01
ATR (14)
3.21
5.31% of price
Realised vol 30D
55.5%
Annualised
Bollinger upper
68.34
20, 2σ
Bollinger lower
52.42
20, 2σ
50 / 200 cross
Golden
58.97 vs 49.47
Trend bias
Above 200
+22.29%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.26
More volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
55.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-39.8%
Peak to trough
Max drawdown 5Y
-68.9%
Peak to trough
ATR 14
3.21
5.31% of price
Beta (reported)
1.22
5Y monthly, from filing
Short interest
Shares short
12.49M
Prior 11.79M
Change vs prior
+6.0%
Shorts adding
% of float
15.80%
Elevated
% of shares out
8.20%
Against total outstanding
Days to cover
6.3
Crowded exit
Float
103.69M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 29, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Sep 9, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Aug 5, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Jul 8, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Jul 7, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Jun 29, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jun 24, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jun 8, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| May 7, 26 | UBS | MAINTAINED | Neutral | Neutral |
| May 7, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| May 7, 26 | TD Cowen | MAINTAINED | Hold | Hold |
Dividends & splits
Forward rate$0.20 / yr
Forward yield0.33%
5-year avg yield0.32%
Payout ratio38.46%
Ex-dividend dateSep 21, 2026
Next pay dateOct 7, 2026
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-14
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-07-30
Offering Registrations
S-3ASR · 2026-06-12
Corporate Changes & Voting Matters
8-K/A · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-21
Corporate Changes & Voting Matters
8-K · 2026-05-15
Headlines
3 Cash-Producing Stocks We Steer Clear Of
StockStory · 3h ago
Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution
Business Wire · 1d ago
Are Options Traders Betting on a Big Move in Bruker Stock?
Zacks · 2d ago
1 Surging Stock to Target This Week and 2 We Question
StockStory · 2d ago
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel
Zacks · 5d ago
Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
Business Wire · 9d ago
Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound
MarketBeat · 11d ago
Is Bruker (BRKR) Using Flagship Academic NMR Deals To Deepen Its High-End Moat?
Simply Wall St. · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.